Small Business Innovation Research (SBIR) Program is sponsored by U.S. Centers for Disease Control and Prevention (CDC). Encourages small businesses to develop innovative health technologies.

About the Small Business Innovation Research Program | Tech and Innovation | CDC Skip directly to site content About the Small Business Innovation Research Program The Small Business Innovation Research (SBIR) program is a set-aside program (3.

2% of an agency's extramural budget) for domestic small business concerns to engage in relevant Federal Research/Research and Development (R/R&D) with the potential for commercialization and public benefit. The SBIR program was established under the Small Business Innovation Development Act of 1982 (P. L.

97-219). CDC's SBIR program is under the stewardship of the Office of Science (OS). CDC is committed to ensuring a competitive award process that results in mission-relevant projects of scientific excellence and technological innovation with the potential for commercialization.

The Program's specific objectives are to: Stimulate technological innovation; Use small business to meet Federal R/R&D needs; Foster and encourage participation by emerging and undercapitalized SBCs in technological innovation and, Increase private sector commercialization of innovations derived from Federal R/R&D, thereby increasing competition, productivity and economic growth Eligible institutions/organizations Funding is awarded competitively and is available for only Phases I and II of the SBIR Program: Phase I contract awards up to $243,500 for approximately 6 months and Phase I grant awards up to $314,363* for project timeline that is typically 6 months (but may extend to 12 months) to support exploration of the technical merit or feasibility of an idea or technology.

Phase II awards projects that expand Phase I results. Awards can range up to $2,095,748* for a project period of up to 2 years. During this time, the R&D work is performed, and the developer evaluates commercialization potential.

Phase III is the period during which Phase II innovation moves from the laboratory into the marketplace. At this stage, the small business must find funding in the private sector or other non-SBIR federal agency funding. * CDC has a waiver from the Small Business Administration to exceed these budgets for CDC's Grant Topic Areas of Interest.

Applicants are strongly encouraged to contact CDC program officials early in the application planning process and before submitting any application in excess of the total award amounts listed above. CDC currently participates in SBIR Omnibus/Parent Clinical Trial Not Allowed Funding Opportunity Announcement ( PA-24-245 ) and SBIR Omnibus/Parent Clinical Trial Required Funding Opportunity Announcement ( PA-24-246 ).

See HHS Program Descriptions document pages 164-194 for CDC's research topics of interest. CDC participates along with the NIH in the PHS-2025-1 SBIR Contract Solicitation The contract solicitation receipt date was October 18, 2024, 5 p. m.

EDT. HHS held the Contract Solicitation Pre-proposal webinar (PHS-2025-1), on September 23, 2024, to discuss the PHS-2025-1 solicitation. SBIR report fraud, waste, and abuse What types of fraud are found in the SBIR Programs?

See Fraud, Waste, and Abuse details. Which SBIR rules should you become particularly familiar with? See Fraud, Waste, and Abuse details.

What happens if you break the rules? See Fraud, Waste, and Abuse details. For more information or to report wrongdoing HHS Small Business Innovation Research (SBIR) Fraud HHS OIG Hotline Operations Please direct all inquiries to: Office of Science, SBIR@cdc.

gov , or 404-718-1386. Technology Transfer Office ; Office of Science The Technology Transfer Office partners with industry, academia, non-profits, and other government agencies to improve public health.